214 related articles for article (PubMed ID: 14998080)
1. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state.
Breilh D; Jougon J; Djabarouti S; Gordien JB; Xuereb F; Velly JF; Arvis P; Landreau V; Saux MC
J Chemother; 2003 Dec; 15(6):558-62. PubMed ID: 14998080
[TBL] [Abstract][Full Text] [Related]
2. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
Wacke R; Förster S; Adam U; Mundkowski RG; Klar E; Hopt UT; Drewelow B
J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
[TBL] [Abstract][Full Text] [Related]
4. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
Höffken G; Barth J; Rubinstein E; Beckmann H;
Infection; 2007 Dec; 35(6):414-20. PubMed ID: 18034211
[TBL] [Abstract][Full Text] [Related]
5. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given in different concentrations in a wick before cataract surgery.
Ong-Tone L
J Cataract Refract Surg; 2008 May; 34(5):819-22. PubMed ID: 18471639
[TBL] [Abstract][Full Text] [Related]
6. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients.
Esposito S; Noviello S; D'Errico G; Motta G; Passali D; Aimoni C; Pilucchi S; Fallani S; Cassetta MI; Mazzei T; Novelli A
J Antimicrob Chemother; 2006 Apr; 57(4):789-92. PubMed ID: 16504997
[TBL] [Abstract][Full Text] [Related]
7. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
[TBL] [Abstract][Full Text] [Related]
8. Conjunctival concentrations of a new ophthalmic solution formulation of moxifloxacin 0.5% in cataract surgery patients.
Lindstrom R; Lane S; Cottingham A; Smith S; Sall K; Silverstein S; Shettle L; Walters T; Faulkner R; Cockrum P; Teuscher N
J Ocul Pharmacol Ther; 2010 Dec; 26(6):591-5. PubMed ID: 20925517
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients.
Kees MG; Weber S; Kees F; Horbach T
J Antimicrob Chemother; 2011 Oct; 66(10):2330-5. PubMed ID: 21729931
[TBL] [Abstract][Full Text] [Related]
10. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Hariprasad SM; Shah GK; Mieler WF; Feiner L; Blinder KJ; Holekamp NM; Gao H; Prince RA
Arch Ophthalmol; 2006 Feb; 124(2):178-82. PubMed ID: 16476886
[TBL] [Abstract][Full Text] [Related]
11. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic integration of moxifloxacin in rabbits after intravenous, intramuscular and oral administration.
Fernández-Varón E; Bovaira MJ; Espuny A; Escudero E; Vancraeynest D; Cárceles CM
J Vet Pharmacol Ther; 2005 Aug; 28(4):343-8. PubMed ID: 16050813
[TBL] [Abstract][Full Text] [Related]
13. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
[TBL] [Abstract][Full Text] [Related]
14. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty.
Malincarne L; Ghebregzabher M; Moretti MV; Egidi AM; Canovari B; Tavolieri G; Francisci D; Cerulli G; Baldelli F
J Antimicrob Chemother; 2006 May; 57(5):950-4. PubMed ID: 16551691
[TBL] [Abstract][Full Text] [Related]
15. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery.
De Smet J; Colin P; De Paepe P; Ruige J; Batens H; Van Nieuwenhove Y; Vogelaers D; Blot S; Van Bocxlaer J; Van Bortel LM; Boussery K
J Antimicrob Chemother; 2012 Jan; 67(1):226-9. PubMed ID: 21987240
[TBL] [Abstract][Full Text] [Related]
16. Penetration of moxifloxacin into liver tissue.
Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
[TBL] [Abstract][Full Text] [Related]
17. Penetration and accumulation of moxifloxacin in uterine tissue.
Stass H; Kubitza D; Aydeniz B; Wallwiener D; Halabi A; Gleiter C
Int J Gynaecol Obstet; 2008 Aug; 102(2):132-6. PubMed ID: 18501909
[TBL] [Abstract][Full Text] [Related]
18. Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
Fukuda M; Yamada M; Kinoshita S; Inatomi T; Ohashi Y; Uno T; Shimazaki J; Satake Y; Maeda N; Hori Y; Nishida K; Kubota A; Nakazawa T; Shimomura Y
Adv Ther; 2012 Apr; 29(4):339-49. PubMed ID: 22529026
[TBL] [Abstract][Full Text] [Related]
19. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
McCulley JP; Caudle D; Aronowicz JD; Shine WE
Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
[TBL] [Abstract][Full Text] [Related]
20. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
